Improving the outlook for children with Philadelphia positive ALL
Unravelling clinical heterogeneity in Philadelphia positive ALL
Can we prevent leukaemia in children?
Modelling prophylactic (microbial) prevention of childhood acute lymphoblastic leukaemia
Investigating the genetic pathways that control leukaemia growth
RNA helicase DDX3X regulates JAK-STAT signalling in acute lymphoblastic leukaemia
Using digital technology to improve our understanding of rhabdomyosarcoma
Deep learning: An integrated approach to define clinical significance to components of the tumour microenvironment of rhabdomyosarcomas
Using an antibody 'smart bomb' to help the body fight cancer
Targeting Myeloid-Derived Suppressor Cells (MDSCs) and Tumour-Associated Macrophages (TAMs) with the anti-CD33 immunotoxin Gemtuzumab ozogamicin to restore anti-cancer immunity
Using repurposed drugs to repair the damage that causes acute myeloid leukaemia
Targeting mutant NRAS in paediatric AML
"Getting it right first time" for children with renal tumours
Improving prediction of relapse, treatment delivery and outcomes for children with renal tumours in the UK
Investigating the potential benefits of proton beam therapy for abdominal tumours
The use of proton beam therapy to improve outcomes in childhood abdominal tumours
Repurposing existing drugs to improve outcomes in Ewing sarcoma
Repurposing of drugs targeting drug resistant self-renewing Ewing’s sarcoma cells to accelerate new treatments into clinical trials to improve outcomes.